DEI BioPharma completed the acquisition of a 51% stake in Neocell Bio-Technologies.

Synopsis

DEI BioPharma, a producer of medicines and vaccines, completed the acquisition of a 51% stake in Neocell Bio-Technologies, a provider of contract research, development, and technology transfer services for biologics and biosimilars. Financial terms were not disclosed.

Principals

target

Neocell Bio-technologies Private

bidder

Dei Biopharma

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

jeetendra kashinath ambulge

CEO at NEOCELL BIO-TECHNOLOGIES PRIVATE LIMITED

Manager

target

Deal

n/a

Total Value

Bidder Team (1)

mathias magoola

Managing Director at DEI BIOPHARMA LTD

Manager

bidder

Deal

n/a

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy